• Email
  • Help

This page brings together the Agency's latest information on cancer. It lists:

the ten newest and recently updated medicines authorised for the treatment of cancer in the European Union (EU);

the most recent opinions on anti-cancer medicines that are pending authorisation by the European Commission (EC);

the latest cancer-related news and press releases;

the Agency's events on cancer-related topics.

New and recently updated medicines

Opinions pending EC decision



  • 03/12/2015 - 04/12/2015


    Innovation and Biomarkers in Cancer Drug Development (IBCD) 2015

    Innovation and Biomarkers in Cancer Drug Development (IBCD) 2015 will shine a spotlight on multi-stakeholder approaches to cancer drug development with new cancer biomarkers in a scientific programme which will include input from regulators, industry, academia, patients and payers. Without a doubt, the combined efforts of the European Organisation for Research and Treatment of Cancer (EORTC), an academic research organisation, the US National Cancer Institute (NCI), a governmental institution, the European Medicines Agency (EMA), a regulatory agency, and the American Association for Cancer Research (AACR), a professional scientific association, ensure that a unique programme focusing on multi-stakeholder approaches to cancer drug development will emerge. A rich scientific programme for IBCD 2015 has been developed covering topics of interest to all cancer drug development stakeholders. Registration open until 12/11/2015. ... Read more

  • 30/04/2015


    European Medicines Agency (EMA)/European Society for Medical Oncology (ESMO) Rare Cancers Europe initiative: Joint workshop on chordoma as a model for very rare cancers

    Following the workshop on the methodology of clinical trials in rare cancers held in October 2014, the European Medicines Agency (EMA) and the European Society for Medical Oncology (ESMO) Rare Cancers Europe initiative will review a real case scenario on one single rare cancer and discuss together how to facilitate the development of promising therapies in spite of rarity. The aim of this workshop, which focuses on chordoma, is to discuss scientific and regulatory evidence requirements for rare diseases, main challenges and identify possible methodological solutions that could work for this and other very rare cancers. The meeting foresees the participation of oncologists, statisticians, methodologists, patient advocates and industry. A meeting report will be published on the EMA and ESMO websites. Registration by invitation only. Places limited. ... Read more

  • 02/05/2012


    Workshop on health-related quality of life in oncology

    The workshop on health-related quality of life (HRQoL) in oncology aims to bring together relevant experts and discuss HRQoL issues with a focus on available instruments (including patient-reported outcomes [PRO]) and their utilisation in oncology clinical trials. The intention is to generate a HRQoL/PRO appendix to the anticancer medicines guideline. Registration by invitation only. ... Read more

  • 03/12/2010


    High-grade glioma expert group

    The European Medicines Agency is holding this expert meeting to understand and discuss how anti-cancer medicines should be developed to treat children with high-grade glioma, a disease with a dismal prognosis and high unmet needs. Recent biological and clinical data, as well as experience from paediatric trials, is being discussed. Preliminary consequences for paediatric trials and further questions are being identified. ... Read more